Kamalesh Kumar Sankhala, MD
Division of Hematology & Oncology, The University of Texas, USA
Kamalesh Sankhala has received his medical degree (MD) and residency training in Internal Medicine from University of Rajasthan, India and Fellowship in Medical Oncology from University of Texas Health Science Center San Antonio, Texas. Currently he is working as a clinical investigator at the Institute for Drug Development (IDD), Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio. Since 2003. Dr. Sankhala has been working in the area of Oncology Drug Development Research. IDD is known for being the largest Oncology drug development research program in the United States and has set unprecedented standards for the development of novel anti-cancer agents, playing a key role in the preclinical and clinical development of 20 new cancer drugs that were subsequently approved by the Food and Drug Administration (FDA). Since he joined IDD in 2006, Dr. Sankhala has worked as clinical investigator on about 22 investigational clinical studies on novel anti-cancer drugs; additionally he has been a sub-investigator on 80 other clinical studies. He is the recipient of American Society of Clinical Oncology Foundation Merit Award and AACR-NCI scholarship for Molecular Biology in Clinical Oncology. He has authored several research articles and is a reviewer of reputed Journals in the field of oncology.
Translational research of novel anti-cancer agents and on studying the pre-clinical and clinical aspect of these agents. His clinical experties include management of patients with Sarcoma, head & neck and gynecology cancers.
Cancer Science & Therapy received 5332 citations as per Google Scholar report